TY - JOUR T1 - A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA). JO - Journal of Clinical Oncology PY - 2019/05/20 AU - Powles T AU - Meeks JJ AU - Galsky MD AU - Van Der Heijden MS AU - Nishiyama H AU - Al-Ahmadie H AU - Gupta AK AU - Ye J AU - Donegan SE AU - Ghiorghiu DC AU - Ferro S et al ED - DO - DOI: 10.1200/jco.2019.37.15_suppl.tps4592 PB - American Society of Clinical Oncology (ASCO) VL - 37 IS - 15_suppl SP - TPS4592 EP - TPS4592 Y2 - 2025/09/19 ER -